“The court’s materiality analysis raises issues faced by all public companies.”
In this article, John S. Summers and Michael J. Newman discuss the recent Matrixx Initiatives Inc. v. Siracusano case, in which the U.S. Supreme Court reviewed its “total mix” standard for materiality in Rule 10b-5 cases, and analyze the effects it may have outside the pharmaceutical industry.
This article was originally published in The Legal Intelligencer.
